Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience.

Autor: Thor A; Department of Clinical Science, Intervention and Technology, Division of Urology, Karolinska Institute, Stockholm, Sweden.; Department of Urology, Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden., Negaard HFS; Department of Oncology, Oslo University Hospital, Oslo, Norway., Grenabo Bergdahl A; Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Department of Urology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden., Almås B; Department of Urology, Haukeland University Hospital, Bergen, Norway., Melsen Larsen S; Department of Urology, Oslo University Hospital, Oslo, Norway., Lundgren PO; Department of Clinical Science, Intervention and Technology, Division of Urology, Karolinska Institute, Stockholm, Sweden.; Department of Urology, Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden., Gerdtsson A; Department of Clinical Science, Intervention and Technology, Division of Urology, Karolinska Institute, Stockholm, Sweden.; Department of Urology, Skåne University Hospital, Malmö, Sweden.; Institution of Translational Medicine, Lund University, Malmö, Sweden., Halvorsen D; Department of Urology, St. Olavs University Hospital, Trondheim, Norway., Johannsdottir B; Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Stockholm, Sweden., Jansson AK; Department of Immunology, Genetics & Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden., Hellström M; Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden., Wahlqvist R; Department of Urology, Oslo University Hospital, Oslo, Norway., Langberg CW; The Cancer Centre, Oslo University Hospital, Oslo, Norway., Hedlund A; Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden., Akre O; Department of Urology, Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.; Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden., Glimelius I; Department of Immunology, Genetics & Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden., Ståhl O; Department of Oncology, Skåne University Hospital, Lund, Sweden.; Department of Clinical Sciences, Lund University, Lund, Sweden., Haugnes HS; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.; Department of Clinical Medicine, UIT - The Arctic University of Norway, Tromsø, Norway., Cohn-Cedermark G; Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Stockholm, Sweden.; Department of Oncology - Pathology, Karolinska Institute, Stockholm, Sweden., Kjellman A; Department of Clinical Science, Intervention and Technology, Division of Urology, Karolinska Institute, Stockholm, Sweden.; Department of Urology, Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden., Tandstad T; The Cancer Clinic, St. Olavs University Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Publikováno v: European urology open science [Eur Urol Open Sci] 2024 Jun 11; Vol. 65, pp. 13-19. Date of Electronic Publication: 2024 Jun 11 (Print Publication: 2024).

Association of physical activity with overall mortality among long-term testicular cancer survivors: A longitudinal study.

Autor: Thorsen L; National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Department of Clinical Service, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Courneya KS; Faculty of Kinesiology, Sport and Recreation, University of Alberta, Edmonton, Canada., Steene-Johannessen J; Department of Sports Medicine, Norwegian School of Sports Sciences, Oslo, Norway., Gran JM; Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway., Haugnes HS; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.; Institute of Clinical Medicine, University of Tromsø - The Arctic University, Tromsø, Norway., Negaard HFS; Department of Oncology, Oslo University Hospital, Oslo, Norway., Kiserud CE; National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Fosså SD; National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.; Faculty of Medicine, University of Oslo, Oslo, Norway.

Publikováno v: International journal of cancer [Int J Cancer] 2023 Oct 15; Vol. 153 (8), pp. 1512-1519. Date of Electronic Publication: 2023 Jun 19.

Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group.

Autor: Gerdtsson A; Department of Clinical Science, Intervention and Technology, Division of Urology, Karolinska Institutet, Stockholm, Sweden; Department of Urology, Skåne University Hospital, Malmö, Sweden. Electronic address: axel.gerdtsson@ki.se., Thor A; Department of Clinical Science, Intervention and Technology, Division of Urology, Karolinska Institutet, Stockholm, Sweden; Department of Urology, Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden., Grenabo Bergdahl A; Department of Urology, Gothenburg University, Gothenburg, Sweden; Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden., Almås B; Department of Urology, Haukeland University Hospital, Bergen, Norway., Håkansson U; Gastrocenter, Lund, Sweden., Törnblom M; Department of Clinical Science and Education, Section of Urology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden; Department of Surgery, Visby County Hospital, Visby, Sweden., Negaard HFS; Department of Oncology, Oslo University Hospital, Oslo, Norway., Glimelius I; Department of Immunology, Genetics and Pathology, Unit of Clinical and Experimental Oncology, Uppsala University, Uppsala, Sweden., Halvorsen D; Department of Urology, St. Olavs University Hospital, Trondheim, Norway., Karlsdóttir Á; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Sagstuen Haugnes H; Department of Oncology, University Hospital of North Norway, Tromsø, Norway; Department of Clinical Medicine, UIT-The Arctic University of Norway, Tromsø, Norway., Engen Andreassen K; Department of Oncology, Oslo University Hospital, Oslo, Norway., Melsen Larsen S; Department of Urology, Oslo University Hospital, Oslo, Norway., Holmberg G; Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden., Wahlqvist R; Department of Urology, Oslo University Hospital, Oslo, Norway., Tandstad T; The Cancer Clinic, St. Olavs University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Cohn-Cedermark G; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Stockholm, Sweden., Ståhl O; Department of Oncology, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences, Lund University, Lund, Sweden., Kjellman A; Department of Clinical Science, Intervention and Technology, Division of Urology, Karolinska Institutet, Stockholm, Sweden; Department of Urology, Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.

Publikováno v: European urology oncology [Eur Urol Oncol] 2022 Apr; Vol. 5 (2), pp. 235-243. Date of Electronic Publication: 2021 Mar 06.

Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study.

Autor: Hellesnes R; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.; Department of Clinical Medicine, UiT, The Arctic University of Norway, Tromsø, Norway., Myklebust TÅ; Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway.; Department of Registration, Cancer Registry of Norway, Oslo, Norway., Bremnes RM; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.; Department of Clinical Medicine, UiT, The Arctic University of Norway, Tromsø, Norway., Karlsdottir Á; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Kvammen Ø; Department of Oncology, Ålesund Hospital, Ålesund, Norway., Negaard HFS; Department of Oncology, Oslo University Hospital, Oslo, Norway., Tandstad T; The Cancer Clinic, St. Olav's University Hospital, Trondheim, Norway.; Department of Clinical and Molecular Medicine, The Norwegian University of Science and Technology, Trondheim, Norway., Wilsgaard T; Department of Community Medicine, UiT, The Arctic University of Norway, Tromsø, Norway., Fosså SD; Department of Registration, Cancer Registry of Norway, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Haugnes HS; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.; Department of Clinical Medicine, UiT, The Arctic University of Norway, Tromsø, Norway.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Feb 01; Vol. 39 (4), pp. 308-318. Date of Electronic Publication: 2020 Dec 23.

Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era.

Autor: Hellesnes R; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.; Department of Clinical Medicine, UiT The Arctic University, Tromsø, Norway., Kvammen Ø; Department of Oncology, Ålesund Hospital, Ålesund, Norway.; Department of Clinical and Molecular Medicine, The Norwegian University of Science and Technology, Trondheim, Norway., Myklebust TÅ; Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway.; Department of Registration, Cancer Registry of Norway, Oslo, Norway., Bremnes RM; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.; Department of Clinical Medicine, UiT The Arctic University, Tromsø, Norway., Karlsdottir Á; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Negaard HFS; Department of Oncology, Oslo University Hospital, Oslo, Norway., Tandstad T; Department of Clinical and Molecular Medicine, The Norwegian University of Science and Technology, Trondheim, Norway.; The Cancer Clinic, St. Olav's University Hospital, Trondheim, Norway., Wilsgaard T; Department of Community Medicine, UiT The Arctic University, Tromsø, Norway., Fosså SD; Department of Registration, Cancer Registry of Norway, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Haugnes HS; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.; Department of Clinical Medicine, UiT The Arctic University, Tromsø, Norway.

Publikováno v: International journal of cancer [Int J Cancer] 2020 Jul 01; Vol. 147 (1), pp. 21-32. Date of Electronic Publication: 2019 Nov 01.